Showing results (121-130 of 179) with videos related to

Sort By:
Pageof 18
Journal of the National Cancer Institute|March 8, 2013
RanGTPase: a candidate for Myc-mediated cancer progressionHiu-Fung Yuen, Vignesh-Kumar Gunasekharan, Ka-Kui Chan, et al.
Plos One|June 14, 2013
BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesotheliomaSara Busacca, Alex D Chacko, Astero Klabatsa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2011
Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathwaysHiu-Fung Yuen, Ka-Kui Chan, Claire Grills, et al.
The Lancet. Respiratory Medicine|January 30, 2021
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trialDean A Fennell, Amy King, Seid Mohammed, et al.
Journal of Cell Science|March 19, 2020
EML4-ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7Laura O'Regan, Giancarlo Barone, Rozita Adib, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 1, 2013
Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trialMarianne C Nicolson, Dean A Fennell, David Ferry, et al.
The Lancet. Respiratory Medicine|May 13, 2024
Leveraging the pleural space for anticancer therapies in pleural mesotheliomaKevin G Blyth, Prasad S Adusumilli, Philippe Astoul, et al.
The Journal of Molecular Diagnostics : JMD|January 19, 2012
Implications for powering biomarker discovery studiesSian M Dibben, Robert J Holt, Timothy S Davison, et al.
Pageof 18